We aimed to evaluate efficacy and safety of ticagrelor vs. clopidogrel in the non-ST-elevation acute coronary syndrome ( NSTE-ACS ) subgroup of the PLATO trial , in the total cohort , and in the subgroups managed with and without revascularization within 10 days of randomization .